BR100 Increased By (0.64%)
BR30 Increased By (0.86%)
KSE100 Increased By (0.39%)
KSE30 Increased By (0.41%)
BECO 6.10 Increased By ▲ 0.33 (5.72%)
BML 53.45 Increased By ▲ 0.45 (0.85%)
BOP 34.34 Increased By ▲ 0.35 (1.03%)
CNERGY 8.16 Increased By ▲ 0.05 (0.62%)
DCL 12.21 Increased By ▲ 0.01 (0.08%)
FCCL 53.39 Increased By ▲ 0.56 (1.06%)
FCSC 5.14 Increased By ▲ 0.07 (1.38%)
FFL 18.04 Increased By ▲ 0.09 (0.5%)
FNEL 1.32 Increased By ▲ 0.03 (2.33%)
HUMNL 10.94 Increased By ▲ 0.06 (0.55%)
KEL 8.13 Increased By ▲ 0.11 (1.37%)
KOSM 5.27 Decreased By ▼ -0.25 (-4.53%)
MLCF 87.23 Increased By ▲ 0.72 (0.83%)
NBP 187.00 Increased By ▲ 1.84 (0.99%)
PACE 10.67 Increased By ▲ 0.09 (0.85%)
PAEL 39.80 Increased By ▲ 0.38 (0.96%)
PIAHCLA 26.15 Decreased By ▼ -0.07 (-0.27%)
PIBTL 17.37 Increased By ▲ 0.70 (4.2%)
PPL 229.10 Increased By ▲ 0.92 (0.4%)
PRL 34.78 Increased By ▲ 0.10 (0.29%)
PTC 66.78 Increased By ▲ 1.45 (2.22%)
SEARL 90.62 Increased By ▲ 0.49 (0.54%)
SSGC 26.99 Increased By ▲ 0.39 (1.47%)
TELE 8.55 Increased By ▲ 0.27 (3.26%)
THCCL 58.45 Decreased By ▼ -0.05 (-0.09%)
TPLP 8.64 Increased By ▲ 0.42 (5.11%)
TREET 24.56 Increased By ▲ 0.03 (0.12%)
TRG 69.70 Decreased By ▼ -0.01 (-0.01%)
WAVES 9.96 Increased By ▲ 0.02 (0.2%)
WTL 1.29 Increased By ▲ 0.01 (0.78%)
Business & Finance

Pakistani pharma Searle appoints chairman

  • Also appoints Zubair Razzak Palwala as a member of the Audit Committee
Published January 14, 2026 Updated January 14, 2026 01:45pm

The Searle Company Limited (SEARL) announced key appointments at the company on Wednesday.

The company, in a notice to the Pakistan Stock Exchange (PSX), shared that the Board of Directors, in its meeting held on Wednesday, January 14, had appointed the Chairman of the Board of Directors of the company.

The listed company informed the PSX that Arshad Anis has been appointed as the chairman of the company with effect from today, January 14, 2026.

“Moreover, the board has also appointed Zubair Razzak Palwala as a member of the Audit Committee in place of Adnan Asdar Ali,” the company said.

READ MORE: SEARL wins DRAP nod for Denosumab injections in Pakistan

SEARL was incorporated in Pakistan as a private limited company in 1965 and was later converted into a public limited company. The principal activity of the company is the manufacturing and sale of pharmaceutical, consumer health and nutritional products.

SEARL is a subsidiary of International Brands (Private) Limited.


Comments

200 characters remaining